The lifetime prevalence of alcohol problems is thought to be between 13.7 and 23.5 percent, indicating that these problems are common in ambulatory patients.1 Family physicians play an important role in identifying these patients and intervening to the degree appropriate for the severity of disease and the patient's willingness to change.
Patients who have alcohol dependence may require detoxification to prevent alcohol withdrawal syndrome (AWS). When clinically appropriate, detoxification can be initiated in the ambulatory setting.2 Most ambulatory patients with alcohol dependence can be detoxified quickly and safely without the use of psychoactive drugs.
|Key clinical recommendation
|All adult and adolescent patients should be screened to detect problem drinking.
|Patients who screen positive for problem drinking should receive a brief intervention designed to moderate their drinking.
|Patients with serious psychiatric involvement (e.g., suicidal ideation), concurrent acute illness, or severe AWS-related symptoms, or those who are at high risk for developing delirium tremens, are best detoxified in inpatient settings.
|Long-acting benzodiazepines are the drugs of choice for monotherapy in patients with AWS.
|A validated scale such as the CIWA-Ar should be used to monitor the response to therapy.
Screening to detect problem drinking is recommended in all adult and adolescent patients.3 Direct questions about the quantity and frequency of alcohol consumption (to detect hazardous drinkers) and the four-item CAGE questionnaire4 (to detect dependent drinkers) appear to be the most useful tools in primary care settings.5,6 The CAGE questionnaire (feeling the need to Cut down, Annoyed by criticism, Guilty about drinking, and drinking in the morning to treat tremulousness or a hangover [Eye opener]) is the most popular tool to evaluate patterns of alcohol use.
At-risk drinking is defined as more than 14 drinks per week in men under age 65 and more than seven drinks per week in women and all adults aged 65 and older. One standard drink is equal to 12 oz of regular beer, 5 oz of wine, or 1.5 oz of distilled spirits. Heavy drinkers should receive a brief intervention designed to moderate their drinking.7,8 These interventions are based on motivational interviewing techniques (Table 1).9 Approximately 5 percent of the patients in a typical adult primary care practice would be expected to have alcohol dependence.10 In patients without acute medical or surgical problems, about one third would be expected to develop mild to moderate AWS (e.g., tremulousness, tachycardia), and only a small minority would be expected to develop severe AWS if they abruptly stopped drinking.1,11–13 In one study11 of 1,024 ambulatory patients undergoing detoxification without psychoactive drugs, 3.7 percent experienced hallucinations, 1.2 percent had alcohol withdrawal seizures, and 1 percent developed delirium tremens.
|Express your concern about drinking. Be specific.
|“I'm concerned about how your drinking has affected your liver.”
|Emphasize that change is the patient's responsibility.
|“Only you can make a decision to change and make your life better.”
|Tell the patient specifically what you want him or her to do.
|“I would like you to go to a treatment center for an evaluation.”
|Provide some alternatives to your recommendation.
|“You could just think about what I have said or go to an Alcoholics Anonymous meeting.”
|“I know this may be hard for you to talk about.”
|“You deserve better, and you can get better if you reach out for help.”
Patients who are at risk for AWS may benefit from pharmacotherapy. Outpatient detoxification is an effective, safe, and low-cost treatment for patients with mild to moderate symptoms of AWS.14 An appropriate candidate is a patient who meets the criteria for alcohol dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)15 and is at low to moderate risk for AWS (Tables 216–20 and 315). Patients with serious psychiatric involvement (e.g., suicidal ideation), concurrent acute illness, or severe AWS-related symptoms, or those who are at high risk for developing delirium tremens, are best detoxified in inpatient settings.12,16–20 Because polysubstance abuse is common in patients with alcohol dependence,21 physicians may wish to consider performing urine toxicology tests when the history or physical examination indicates that such screening may be helpful. Patients who are dependent on opioids or benzodiazepines may require detoxification from these substances as well.
|Alcohol dependence with evidence of tolerance and withdrawal
|Coexisting acute or chronic illness requiring inpatient treatment
|Current severe alcohol withdrawal, especially with delirium
|No possibility for follow-up
|No reliable contact person to monitor the patient
|Seizure disorder or history of severe alcohol withdrawal seizures
|Coexisting benzodiazepine dependence
|History of unsuccessful outpatient detoxification
|High risk for severe alcohol withdrawal or delirium tremens16–20
|Age > 40 years
|Heavy drinking > 8 years
|Drinking > 100 g of ethanol daily (e.g., about one pint of liquor or eight 12-oz cans of beer)
|Symptoms and signs of withdrawal when not drinking
|Random blood alcohol concentration > 200 mg per dL
|Elevated mean corpuscular volume
|Elevated blood urea nitrogen
Alcohol Withdrawal Syndrome
The goal of detoxification is to control the symptoms of AWS and to prevent alcohol withdrawal seizures, withdrawal delirium, and deaths from complications of AWS. Ultimately, the purpose of outpatient detoxification is to facilitate the patient's entry into an alcohol rehabilitation program.
AWS represents the unmasking of the adaptation that the brain makes to the chronic presence of alcohol. The symptoms and signs of AWS fall into three main categories: central nervous system (CNS) excitation (e.g., restlessness, agitation, seizures); excessive function of the autonomic nervous system (ANS) (e.g., nausea, vomiting, tachycardia, tremulousness, hypertension); and cognitive dysfunction.
STAGES OF WITHDRAWAL
Stage 1, “minor withdrawal,” usually begins five to eight hours after the last drink and is characterized by anxiety, restlessness, agitation, mild nausea, decreased appetite, sleep disturbance, facial sweating, mild tremulousness, and fluctuating tachycardia and hypertension. Patients are coherent, but they may have mild cognitive impairment.
Stage 2, “major withdrawal,” occurs 24 to 72 hours after the last drink and is characterized by marked restlessness and agitation, moderate tremulousness with constant eye movement, diaphoresis, nausea, vomiting, anorexia, and diarrhea. Patients often have marked tachycardia (i.e., greater than 120 bpm) and systolic blood pressure greater than 160 mm Hg. “Alcoholic hallucinosis,” which consists of auditory or visual hallucinations, may be present. The patient may be disoriented and appear confused, but reorientation often is possible. Seizures—typically grand mal—may occur but are not always preceded by other symptoms. They usually are single seizures that last less than five minutes, but some patients have seizures in salvos of two or three. Status epilepticus is not associated with alcohol withdrawal and indicates another problem.
Stage 3, “delirium tremens,” can occur from 72 to 96 hours after the last drink. It is associated with fever, severe hypertension and tachycardia, delirium, drenching sweats, and marked tremulousness. Causes of death during this stage include head trauma, cardiovascular complications, infections, aspiration pneumonia, and fluid and electrolyte abnormalities.
Nonpharmacologic interventions are important in the management of AWS and include frequent reassurance, reality orientation, and nursing care.22 Patients seem to do best when they are kept in an evenly lit, quiet room, and dark shadows, bright lights, loud noises, and other excessive stimuli are avoided. Liberal intake of noncaffeinated fluids can help prevent dehydration.
Medications are used to prevent or treat the various clinical manifestations of AWS: sedatives for CNS excitation; sympatholytics for excessive ANS activity not controlled by sedatives alone; and neuroleptics as adjunctive therapy for cognitive dysfunction.13
Thiamine supplementation is essential in malnourished patients for the prevention of Wernicke's encephalopathy. Although most candidates for outpatient detoxification probably would not have a thiamine deficiency, the supplement can be given routinely because there are no adverse effects or contraindications to its use.
Long-acting benzodiazepines are the agents of choice for monotherapy in patients with AWS.23,24 The three most common treatment regimens for prevention of AWS are symptom triggered,25 front loading,26 and fixed schedule.27 Dosages for these regimens are given in Table 4.13,26,27 In clinical practice, the effective dosage can vary greatly from one patient to another. Long-acting benzodiazepines such as chlordiazepoxide (Librium) and diazepam (Valium) are preferred because they are the most effective in preventing alcohol withdrawal seizures and delirium. A short-acting benzodiazepine (such as oxazepam [Serax]) that does not have any active metabolites can be used in elderly patients, those in whom oversedation absolutely must be avoided, and those with significant liver disease that might impair their ability to metabolize a long-acting agent.
|FDA-approved: chlordiazepoxide (Librium); initial dose of 50 to 100 mg, followed by repeated doses as needed until agitation is controlled, up to 300 mg per day.
|Off-label: chlordiazepoxide; 25 to 100 mg every hour when CIWA-Ar score > 8.27
|FDA-approved: diazepam (Valium); 10 mg 3 or 4 times in first 24 hours, then 3 or 4 times daily as needed.
|Off-label: diazepam; 20 mg every 1 to 2 hours at first sign of withdrawal until symptoms are improved.26
|Off-label: chlordiazepoxide; 50 mg every 6 hours for four doses, then 25 mg every 6 hours for eight doses.13
|FDA-approved: oxazepam (Serax); 15 to 30 mg 3 or 4 times daily.
|Off-label: lorazepam (Ativan); 0.5 to 1 mg 3 or 4 times daily on a scheduled basis, plus 1 mg every 4 hours if needed for mild symptoms (e.g., CIWA-Ar score between 8 and 14) or 2 mg every 2 hours if needed for moderate symptoms (e.g., CIWA-Ar score > 15).
Some physicians use phenobarbital with great success in patients with AWS. However, barbiturates have not been evaluated clinically as thoroughly as benzodiazepines, have a narrow therapeutic window, may interact with many other medications, and have not been approved by the U.S. Food and Drug Administration for the treatment of patients with AWS.
Well-designed studies have found that clonidine (Catapres) and atenolol (Tenormin) are effective as adjuvant therapy in the treatment of AWS symptoms related to excessive ANS activity, but these studies have not been of adequate size to indicate what effect the agents have on the rate of delirium or seizures.13
There is some evidence to suggest that neuroleptics such as haloperidol (Haldol) are useful in the treatment of delirium in AWS.22 However, because neuroleptics lower the seizure threshold, these agents should be used only after sedation has been achieved with adequate doses of a benzodiazepine.
Carbamazepine (Tegretol) is used extensively in Europe for treatment of AWS, but a recent systematic literature review23 concluded that the evidence to support its use is less than the evidence to support the use of benzodiazepines. There is no evidence of efficacy for phenytoin (Dilantin) in the prevention and treatment of alcohol withdrawal seizures. Treatment with intravenous lorazepam (Ativan) is associated with a significant reduction in the risk of recurrent seizures in patients who develop an alcohol withdrawal seizure.28
Although magnesium may be administered to patients who are deficient, there is no evidence that routine administration of magnesium sulfate is of any benefit unless AWS is accompanied by cardiac arrhythmias.29
MONITORING RESPONSE TO THERAPY
A responsible person should monitor the patient undergoing detoxification and watch for signs and symptoms of worsening AWS. Figure 130 presents an assessment scale that can be used by persons with little or no medical training to monitor the patient. Medical personnel should reevaluate patients on a daily basis if they score more than eight points on this scale despite treatment, experience a seizure, or develop delirium.12 In patients without complications, detoxification usually is complete in four to five days.
Outpatient detoxification alone is not adequate treatment for alcohol dependence: it must be linked to involvement in a formal alcohol rehabilitation program. Many authorities believe that long-term involvement with self-help programs such as Alcoholics Anonymous also is an important part of a patient's long-term recovery.
After sobriety has been achieved, extreme caution should be used in prescribing mood-altering drugs and controlled substances to recovering patients, if they are prescribed at all. Benzodiazepines, in particular, are contraindicated, as they frequently are abused. If there is a clear clinical indication, opioid agonists may be prescribed, but appropriate use should be closely monitored. Antidepressants, especially the sedating tricyclic antidepressants, can be abused by patients with alcohol dependence. Most patients in the early stages of recovery will have depression; this generally responds to counseling without medication. However, some carefully selected patients may benefit from judicious use of antidepressants. Examples include patients who have a well-documented depressive disorder that predates alcohol dependence and responded to antidepressant treatment, and patients with depressive symptoms that persist despite ongoing psychotherapy for alcohol dependence.